CA2388287A1 - Therapies pour la prevention et le traitement du diabete et de l'obesite - Google Patents

Therapies pour la prevention et le traitement du diabete et de l'obesite Download PDF

Info

Publication number
CA2388287A1
CA2388287A1 CA 2388287 CA2388287A CA2388287A1 CA 2388287 A1 CA2388287 A1 CA 2388287A1 CA 2388287 CA2388287 CA 2388287 CA 2388287 A CA2388287 A CA 2388287A CA 2388287 A1 CA2388287 A1 CA 2388287A1
Authority
CA
Canada
Prior art keywords
caffeine
diabetes
adenosine
obesity
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2388287
Other languages
English (en)
Inventor
Terry E. Graham
Erik A. Richter
Farah S.L. Thong
Lindsay E. Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Guelph
Original Assignee
University of Guelph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002349135A external-priority patent/CA2349135A1/fr
Application filed by University of Guelph filed Critical University of Guelph
Priority to CA 2388287 priority Critical patent/CA2388287A1/fr
Publication of CA2388287A1 publication Critical patent/CA2388287A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA 2388287 2001-05-30 2002-05-30 Therapies pour la prevention et le traitement du diabete et de l'obesite Abandoned CA2388287A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2388287 CA2388287A1 (fr) 2001-05-30 2002-05-30 Therapies pour la prevention et le traitement du diabete et de l'obesite

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29446401P 2001-05-30 2001-05-30
US60/294,464 2001-05-30
CA002349135A CA2349135A1 (fr) 2001-05-30 2001-05-30 Therapies pour la prevention et le traitement du diabete et de l'obesite
CA2,349,135 2001-05-30
CA 2388287 CA2388287A1 (fr) 2001-05-30 2002-05-30 Therapies pour la prevention et le traitement du diabete et de l'obesite

Publications (1)

Publication Number Publication Date
CA2388287A1 true CA2388287A1 (fr) 2002-11-30

Family

ID=27171553

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2388287 Abandoned CA2388287A1 (fr) 2001-05-30 2002-05-30 Therapies pour la prevention et le traitement du diabete et de l'obesite

Country Status (1)

Country Link
CA (1) CA2388287A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110105432A (zh) * 2015-04-28 2019-08-09 凯尔格恩有限公司 具有抗肥胖及抗糖尿病功效的肽及其的用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110105432A (zh) * 2015-04-28 2019-08-09 凯尔格恩有限公司 具有抗肥胖及抗糖尿病功效的肽及其的用途
CN110105432B (zh) * 2015-04-28 2022-12-27 凯尔格恩有限公司 具有抗肥胖及抗糖尿病功效的肽及其的用途

Similar Documents

Publication Publication Date Title
Weyer et al. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.
Thong et al. Caffeine-induced impairment of insulin action but not insulin signaling in human skeletal muscle is reduced by exercise
Rodin et al. Effect of insulin and glucose on feeding behavior
Atkinson Naloxone decreases food intake in obese humans
de Montigny Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: preliminary findings
Thong et al. Caffeine-induced impairment of glucose tolerance is abolished by β-adrenergic receptor blockade in humans
AU638992B2 (en) A slimming pharmaceutical composition
US20030007996A1 (en) Therapies for the prevention and treatment of diabetes and obesity
COLLIER et al. The acute effect of fat on insulin secretion
Houben et al. Local 24-h hyperglycemia does not affect endothelium-dependent or-independent vasoreactivity in humans
Xu et al. A1 adenosine receptor antagonism improves glucose tolerance in Zucker rats
van der Zander et al. Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man
Friis et al. Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients
Woo et al. Elevated postprandial insulin levels do not induce satiety in normal-weight humans
Ritter Glucoprivation and the glucoprivic control of food intake
CARLSON et al. Beer-induced prolactin secretion: a clinical and laboratory study of the role of salsolinol
Nacht et al. Thermic effect of food: possible implication of parasympathetic nervous system
Wellman A review of the physiological bases of the anorexic action of phenylpropanolamine (d, l-norephedrine)
Fukagawa et al. Acute effects of fructose and glucose ingestion with and without caffeine in young and old humans
Osundiji et al. Brain glucosamine boosts protective glucoprivic feeding
Benedict et al. The influence of oral tyrosine and tryptophan feeding on plasma catecholamines in man
Addolorato et al. Long-term administration of GHB does not affect muscular mass in alcoholics
Malesci et al. Effect of loxiglumide on gallbladder contractile response to cerulein and food in humans
MURAI et al. Time-dependent increase in plasma prolactin after pituitary stalk section: role of posterior pituitary dopamine
CA2388287A1 (fr) Therapies pour la prevention et le traitement du diabete et de l'obesite

Legal Events

Date Code Title Description
FZDE Dead